GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (OTCPK:MYPHY) » Definitions » 3-Year EPS without NRI Growth Rate

Mayne Pharma Group (Mayne Pharma Group) 3-Year EPS without NRI Growth Rate : -139.20% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Mayne Pharma Group 3-Year EPS without NRI Growth Rate?

Mayne Pharma Group's EPS without NRI for the six months ended in Dec. 2023 was $0.00.

During the past 3 years, the average EPS without NRI Growth Rate was -139.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Mayne Pharma Group was 30.80% per year. The lowest was -139.20% per year. And the median was -12.20% per year.


Competitive Comparison of Mayne Pharma Group's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mayne Pharma Group's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's 3-Year EPS without NRI Growth Rate falls into.



Mayne Pharma Group 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Mayne Pharma Group  (OTCPK:MYPHY) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Mayne Pharma Group 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Mayne Pharma Group (Mayne Pharma Group) Business Description

Traded in Other Exchanges
Address
1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.